RxDoctor Payments Data

Cynthia Tanguilig-Robinson, MD

Geriatric Medicine · Houston, TXNPI 1124231584

Payments from drug & device makers

$349in general payments, 2019–2025

Across 14 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$106
  • Acadia Pharmaceuticals Inc$62
  • Neurocrine Biosciences, Inc.$60
  • Avanir Pharmaceuticals, Inc.$60
  • Sunovion Pharmaceuticals Inc.$27
  • Sumitomo Pharma America, Inc.$18
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$349 in reported general payments places this provider in the 60th percentile of 275 geriatric medicine providers in Texas.

See all geriatric medicine providers in Texas

Medicare billing

Part B allowed, 2024
$141,551
Medicare patients
256
Services billed
1,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban389$128,093
JanuviaSitagliptin Phosphate77$16,776
MyrbetriqMirabegron39$14,019
JardianceEmpagliflozin26$8,673
FarxigaDapagliflozin Propanediol29$7,568
TradjentaLinagliptin29$7,240
TrintellixVortioxetine Hydrobromide46$6,390
Atorvastatin Calcium530$5,638
Cyclosporine24$5,589
Potassium Chloride218$4,962
Levothyroxine Sodium459$4,580
LumiganBimatoprost16$4,444
Duloxetine Hcl185$3,946
GemtesaVibegron16$3,776
VascepaIcosapent Ethyl17$3,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$106$7,56829 claims
Sumitomo Pharma America, Inc.Gemtesa$18$3,77616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 275 geriatric medicine providers in Texas.

Other geriatric medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →